Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Official Title

Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer

Summary:

This study is being done to look at the combination of the drugs atezolizumab and bevacizumab as a maintenance treatment (treatment given after the main treatment to keep the cancer from coming back or worsening) following standard therapy in patients with high grade ovarian, fallopian tube, or primary peritoneal cancer with a mutation (change) in a gene called TP53. Genes are molecules in the body that are made up of deoxyribonucleic acid (DNA) and control how the body's cells behave.

Trial Description

Primary Outcome:

• Number of participants where increase in circulating deoxyribonucleic acid (ctDNA) level is related to progression

Secondary Outcome:

• Disease free survival rate
• Disease free survival rate
• Progression free survival rate
• Progression free survival rate
• Number of participants with disease free survival with change from detectable to undetectable TP53 ctDNA
• Number of participants with disease free survival with change from detectable to undetectable TP53 ctDNA
• Number of participants with adverse events

Atezolizumab and bevacizumab are a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumour growth. When tumour cells start to die, broken down pieces of the tumour's DNA gets released into the blood stream, called circulating tumour DNA (ctDNA). Looking at ctDNA may be useful in determining whether the cancer is responding to treatment. The purpose of this research study is to see whether looking at tumour DNA circulating in the bloodstream can help to determine which patients may respond to atezolizumab and bevacizumab and whether this drug combination is useful, when given as a maintenance treatment for patients with TP53 mutant ovarian, fallopian tube, or primary peritoneal cancer.

View this trial on ClinicalTrials.gov